PMID- 21992557
OWN - NLM
STAT- MEDLINE
DCOM- 20120531
LR  - 20220310
IS  - 1557-7732 (Electronic)
IS  - 1080-7683 (Linking)
VI  - 28
IP  - 1
DP  - 2012 Feb
TI  - Optical coherence tomographic patterns in diabetic macula edema can predict the 
      effects of intravitreal bevacizumab injection as primary treatment.
PG  - 59-64
LID - 10.1089/jop.2011.0070 [doi]
AB  - PURPOSE: To identify optical coherence tomography (OCT) patterns in diabetic 
      macular edema (DME) that were predictive of visual outcomes after intravitreal 
      bevacizumab (IVB) injection. METHODS: This was a retrospective study. We examined 
      31 eyes (24 patients) with clinically significant macular edema that received IVB 
      injections along with macular OCT data. The eyes were categorized into 4 groups 
      by using OCT features: diffuse retinal thickening (DRT), cystoid macular edema 
      (CME), serous retinal detachment (SRD), and vitreomacular interface abnormalities 
      (VMIAs). Changes in retinal thickness, retinal volume, and visual acuity (VA) 
      after IVB injection were compared on the basis of OCT patterns. RESULTS: After 
      IVB injections, changes in VA logarithm of the minimum angle of resolution were 
      -0.06+/-0.36, -0.26+/-0.26, 0.09+/-0.13, and -0.08+/-0.15, respectively, for DRT, CME, 
      SRD, and VMIA patterns. Central macular thickness decreased by 70.5+/-105.5, 
      110.67+/-97.28, 181+/-125.87, and 24.25+/-77.12 mum for the DRT, CME, SRD, and VMIA 
      patterns, respectively. The CME group was associated with a greater reduction in 
      retinal thickness (P=0.009) and volume (P=0.027) with superior VA improvement 
      (P=0.012) as compared with the DRT, SRD, and VMIA groups. CONCLUSIONS: Patients 
      with CME gained greater improvement in visual acuity and macular thickness and 
      volume after IVB injection had been administered as the primary treatment for 
      DME, as compared with other patients. The OCT patterns of DME may indicate the 
      appropriate treatment; we consider these patterns to be prognostic of the 
      response to IVB injection for macular edema.
FAU - Wu, Pei-Chen
AU  - Wu PC
AD  - Department of Ophthalmology, Chang Gung Memorial Hospital, Chiayi, Taiwan.
FAU - Lai, Chien-Hsiung
AU  - Lai CH
FAU - Chen, Ching-Lung
AU  - Chen CL
FAU - Kuo, Chien-Neng
AU  - Kuo CN
LA  - eng
PT  - Journal Article
DEP - 20111012
PL  - United States
TA  - J Ocul Pharmacol Ther
JT  - Journal of ocular pharmacology and therapeutics : the official journal of the 
      Association for Ocular Pharmacology and Therapeutics
JID - 9511091
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiogenesis Inhibitors/administration & dosage/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/*therapeutic use
MH  - Bevacizumab
MH  - Diabetic Retinopathy/*drug therapy/pathology
MH  - Female
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence
MH  - Treatment Outcome
MH  - Visual Acuity/drug effects
EDAT- 2011/10/14 06:00
MHDA- 2012/06/01 06:00
CRDT- 2011/10/14 06:00
PHST- 2011/10/14 06:00 [entrez]
PHST- 2011/10/14 06:00 [pubmed]
PHST- 2012/06/01 06:00 [medline]
AID - 10.1089/jop.2011.0070 [doi]
PST - ppublish
SO  - J Ocul Pharmacol Ther. 2012 Feb;28(1):59-64. doi: 10.1089/jop.2011.0070. Epub 
      2011 Oct 12.